id	证据的ID	总结
2301	1450376262	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema due to carbamazepine.
2300	1450376254	HLA-A *31:01:02 is not associated with risk of Maculopapular Exanthema due to carbamazepine.
2299	1449295707	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Erythema multiforme NOS, Hypersensitivity and Maculopapular Exanthema when treated with carbamazepine in people with Bipolar Disorder, Epilepsy, Neuralgia or Schizophrenia.
2298	1448612304	HLA-A *31:01:02 is associated with Exanthema when treated with carbamazepine in people with Epilepsy.
2297	1448525723	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.
2296	1444935634	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.
2295	1296598666	HLA-A *31:01:02 is associated with increased risk of Drug Toxicity when treated with carbamazepine.
2294	1184988697	HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
2293	1184469272	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
2292	1184469261	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.
2291	1184469204	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.
2290	1184469161	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.
2289	1184468448	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.
2288	1184468437	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.
2287	1184468310	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.
2286	1184467950	HLA-A *31:01:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.
2285	1184467926	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
2284	1184467913	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.
2283	1184466922	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
2282	1184466916	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.
2281	1184466909	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.
2280	1184466701	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
2279	1183702064	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
2278	993944301	HLA-A *31:01:02 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.
2277	993813998	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.
2276	992282434	HLA-A *31:01:02 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.
2275	981482109	HLA-A *31:01:02 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.
2274	PA166105008	Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B

id	类型	评论
1187	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1186	Update	Attached CPIC guideline and removed override. Added conflicting evidence statement.
1185	Update	Added sentence about some no association studies.
1184	Update	Level 1A because of score and guideline.
1183	Update	Added PMID 29288229 to evidence
1182	Update	Added PMID 29610831

最新招商产品更多>>